ADC manufacturer Heidelberg Pharma AG has negotiated a US$931m licensing and investment deal with China’s Huadong Medicine Co, Ltd.
The German inventor of alpha-amanitin antibody conjugates (ATACs) will receive an upfront payment of US$20m and milestone payments of up to US$449m related to its phase 1 multiple myeloma candidate HDP-101 and preclinical prostate cancer ATAC HDP-103, as well as royalties on sales of an undisclosed amount. However, the development partnership also covers two further candidates in early preclinical development as well as options on candidates yet to be generated, which are linked to milestone payments of a further USD 461 million. After a long period of waiting, Heidelberg Pharma has thus achieved a breakthrough in the partnering of Amanitin-coupled antibody technology.
In addition to in-licensing the pipeline, Huadong is taking a 35% or €105 million stake in Heidelberg Pharma, which is funded by dievini Holdung. Huadong will enroll Asian patients in global clinical trials to accelerate product development.
Join 900 US CEOs protest against Ukraine war
OpinionUS Life Science leaders pledge to economically disengage from Russia.
Scenic Biotech BV announces $31m financing
Latest NewsScenic Biotech BV will use an incoming $31m (€28) Series A financing to advance its pipeline of genetic modifiers, a new molecular entity in cancer and rare disease.
·
Kurma Partners closes growth fund at €160m
Latest NewsFrench venture capital expert Kurma Partners has closed its Growth Opportunities Fund at €160m and targets a final closing at €250m.
mRNA for Africa
Latest NewsModerna will build its first mRNA production facility in Kenya, investing up to US$500m.
PhoreMost with new CEO
AppointmentsSince the beginning of March, Dr Neil Torbett has been the new Chief Executive Officer of Cambridge-based PhoreMost Ltd.
Epsilogen raise £30.75m in Series B financing
Latest NewsIgE cancer antibody specialist Epsilogen Ltd has closed a £30.75m round led by Novartis Venture Fund to advance Phase Ib studies with MOv18 IgE in platinum-resistant ovarian cancer.
Syndesi swallowed by Abbvie
Latest NewsAbbVie has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie’s neuroscience portfolio.
Chinese Huadong snaps up Heidelberg Pharma.
Latest NewsADC manufacturer Heidelberg Pharma AG has negotiated a US$931m licensing and investment deal with China’s Huadong Medicine Co, Ltd.
The German inventor of alpha-amanitin antibody conjugates (ATACs) will receive an upfront payment of US$20m and milestone payments of up to US$449m related to its phase 1 multiple myeloma candidate HDP-101 and preclinical prostate cancer ATAC HDP-103, as well as royalties on sales of an undisclosed amount. However, the development partnership also covers two further candidates in early preclinical development as well as options on candidates yet to be generated, which are linked to milestone payments of a further USD 461 million. After a long period of waiting, Heidelberg Pharma has thus achieved a breakthrough in the partnering of Amanitin-coupled antibody technology.
In addition to in-licensing the pipeline, Huadong is taking a 35% or €105 million stake in Heidelberg Pharma, which is funded by dievini Holdung. Huadong will enroll Asian patients in global clinical trials to accelerate product development.
Meletios Therapeutics licences antiviral patent
Latest NewsParis-based Meletios Therapeutics SA has licenced know-how from the Institut Pasteur for the development of a new class of antivirals-
Integra Therapeutics strengthens Science Advisory Board
AppointmentsBarcelona-based Integra Therapeutics appoints George Church to its Scientific Advisory Board.